{
  "id": 18800075,
  "title": "Oral LSD Drug Hits Phase III Endpoints in Anxiety, Depression",
  "url": "https://urgent.news/2026/11/07/oral-lsd-drug-hits-phase-iii-endpoints-in-anxiety-depression",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-11-07T21:46:40.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/meetingcoverage/neicongress/123772"
  },
  "original_language": "en",
  "account": null,
  "summary": "(MedPage Today) -- DT120, an investigational orally disintegrating tablet (ODT) formulation of the psychedelic lysergide (LSD), met the primary endpoints in a pair of phase III trials for generalized anxiety disorder (GAD) and major depressive...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}